US stock futures steady with China trade talks, Q3 earnings in focus
Predictive Oncology Inc. (NASDAQ:POAI), a micro-cap biotech company with a market capitalization of $8.38 million, announced Thursday that its 2025 annual meeting of stockholders will be held on November 25, 2025. The meeting announcement comes as the company’s stock has declined nearly 23% over the past week, though InvestingPro analysis suggests the stock may be undervalued at current levels. The meeting is set to take place at the offices of DLA Piper LLP (US), located at 1001 Liberty Avenue, Suite 500, Pittsburgh, Pennsylvania.
The company’s board of directors set October 24, 2025, as the record date for determining stockholders entitled to receive notice of and vote at the annual meeting. Stockholders who wish to submit proposals or request proxy access for the meeting must do so by October 26, 2025.
According to the company’s statement, definitive proxy materials are expected to be mailed on or about November 3, 2025. Predictive Oncology indicated that it will supplement these materials or, if necessary, postpone the meeting to address any stockholder proposals received before the deadline.
This information is based on a press release statement included in a filing with the Securities and Exchange Commission.
In other recent news, Predictive Oncology Inc. has completed two private investment transactions amounting to approximately $343.5 million. These funds are intended to support the company’s digital asset treasury strategy, specifically focusing on ATH, the native utility token of the Aethir ecosystem. The company raised about $50.8 million in cash through the sale of 4.4 million shares of common stock, priced at $11.6265 per share. Additionally, they secured approximately $292.7 million in notional value through pre-funded warrants exchanged for ATH tokens. Predictive Oncology also announced a 1-for-15 reverse stock split of its common stock, effective September 30, 2025. This move aims to maintain compliance with Nasdaq’s minimum bid price requirements. The company’s shares will continue to trade on the Nasdaq Capital Market under the same symbol, POAI, but will do so on a split-adjusted basis starting September 30.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.